secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001437749-25-026938
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talphera Q2 net loss $3.5M ($0.10/sh); NEPHRO study enrollment accelerates
--------------------------------------------------------------------------

- 15 patients enrolled in NEPHRO registrational study; on track for completion by end of 2025, PMA submission Q1 2026.
- Cash and equivalents $6.8M at June 30, 2025; closed $4.9M first tranche of $14.8M financing.
- Net loss from continuing ops $3.5M vs $3.8M YoY; combined R&D/SG&A expenses $3.7M vs $4.3M.
- Reduced 2025 cash operating expense guidance to $16M-$17M from prior $17M-$19M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774925026938/0001437749-25-026938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774925026938/acrx20250813_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-026938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer